SKHCF:OTO-Sonic Healthcare Ltd (USD)

COMMON STOCK | Diagnostics & Research | OTC Pink

Last Closing

USD 17.466

Change

0.00 (0.00)%

Market Cap

USD 6.62B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sonic Healthcare Ltd provides medical diagnostic services and administrative services and facilities to medical practitioners. The Company's business segments include Pathology, Imaging and Other.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
LZAGF Lonza Group Ltd

N/A

USD 41.97B
LZAGY Lonza Group AG

N/A

USD 41.89B
WUXIF WuXi AppTec Co. Ltd

N/A

USD 17.70B
BMXMF bioMérieux S.A

N/A

USD 12.65B
ERFSF Eurofins Scientific SE

N/A

USD 12.53B
SKHHY Sonic Healthcare Ltd ADR

N/A

USD 8.63B
HNGZY Hangzhou Tigermed Consulting C..

N/A

USD 5.92B
DSRLF DiaSorin S.p.A

N/A

USD 5.73B
VIMGF Vimian Group AB (publ)

N/A

USD 1.45B
MRCHF H.U. Group Holdings Inc

N/A

USD 0.82B

ETFs Containing SKHCF

SGQI 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.56% 26% F 23% F
Dividend Return 1.26% 50% F 33% F
Total Return -20.30% 26% F 24% F
Trailing 12 Months  
Capital Gain -27.01% 57% F 37% F
Dividend Return 2.83% 90% A- 39% F
Total Return -24.19% 63% D 38% F
Trailing 5 Years  
Capital Gain -3.50% 58% F 64% D
Dividend Return 10.32% 57% F 35% F
Total Return 6.82% 55% F 64% D
Average Annual (5 Year Horizon)  
Capital Gain 5.53% 44% F 49% F
Dividend Return 7.22% 43% F 47% F
Total Return 1.69% 50% F 40% F
Risk Return Profile  
Volatility (Standard Deviation) 26.73% 90% A- 77% C+
Risk Adjusted Return 27.00% 62% D 62% D
Market Capitalization 6.62B 91% A- 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector